ММВБ 3 486 -0,6%  Nasdaq 13 900 0,5%  Биткойн 59 040 1,5%  USD/RUB 77,4245 0,8% 
РТС 1 418 -1,6%  S&P500 4 129 0,8%  Нефть 63,1 -0,5%  EUR/RUB 92,1465 0,7% 
Dow 33 801 0,9%  FTSE100 6 916 -0,4%  Золото 1 744 -0,7%  EUR/USD 1,1894 -0,2% 

Aldagen Inc - Профиль

ALDAGEN is a biopharmaceutical company developing proprietary regenerative cell therapies that target significant unmet medical needs. We have four product candidates in clinical trials. Our most advanced product candidate is ALD-101. We are currently conducting a pivotal Phase 3 clinical trial of ALD-101 to evaluate its efficacy in improving umbilical cord blood, or cord blood, transplants used to treat inherited metabolic diseases in pediatric patients. We are also conducting or supporting Phase 1 or Phase 1/2 clinical trials of three other product candidates ALD--151 to improve cord blood transplants used for the treatment of leukemia; ALD-301 to treat critical limb ischemia; and ALD-201 to treat ischemic heart failure.

Адрес

а/я:
Телефон:
Факс:
Вэб:

Менеджмент

Добавить или редактировать инструмент